Anticoagulant monitoring
Last updated: Thursday, 28, October, 2010
| Key Information | Appropriate Tests |
|---|---|
See also Thrombolytic therapy. | |
Heparin (standard, unfractionated) | |
Prior to commencing therapy | FBC, platelet count; baseline APTT, INR if patient on warfarin; PT if warfarin treatment planned. |
During therapy | Platelet counts are recommended on day 5 post commencement of therapy. |
| APTT; check therapeutic interval with laboratory. In the first 24 hours, frequent assessment may be required, but the APTT should not be performed <4 hours after any change in dose. Subsequently, a daily APTT usually suffices if within the therapeutic range. |
| Monitoring not of value. |
| Monitoring not of value. |
If bleeding occurs | APTT; FBC, platelet count. Check other medications with patient and/or from records. Concomitant aspirin or other NSAID increase the risk of bleeding; their effect on platelet function is predictable and testing is not indicated. The possibility of a pre-existent acquired or inherited bleeding disorder should also be considered. |
If progression of thrombosis, or thrombosis in other site(s), causes include: | |
| APTT |
| FBC, platelet count; heparin-dependent platelet antibodies if significant thrombocytopenia is documented and/or significant reduction in platelet count from baseline level. |
| Antithrombin assay: ideally should be deferred until heparin has been ceased, since heparin will reduce the measured level. See under Thrombosis - venous. |
Low molecular weight heparin (LMWH) and heparinoids | The standard dose protocol is based on body weight; monitoring is not usually required except in renal failure or other high risk bleeding situations. Heparin-induced thrombocytopenia is less common than with standard, unfractionated heparin, but may occur: see above. |
Prophylactic SC injection | Monitoring is not required |
Oral anticoagulants | INR. |
Warfarin (Marevan/Coumadin) | |
If bleeding occurs, causes include: | |
| Bleeding risk and INR level. |
| |
| |
| |
| |
| Consult pathologist/pharmacist about drug interactions; consider possibility of recent change in dose, introduction of new, or non-prescribed, medications, herbal and/or dietary supplements. |
| |
| |
| Predictable effect on platelet function; bleeding time does not predict the risk of bleeding and is not indicated. |
| |
| See Bleeding disorders. |
